Alebund Passes HKEX Listing Hearing, Core Product AP301 in Phase III Clinical Trials

NewTimeSpace · 2026/06/14 21:12 · By Yiming Yan

NewTimeSpace News: Alebund Pharmaceuticals (Jiangsu) Limited passed the Main Board listing hearing of the Hong Kong Stock Exchange on June 17, with Jefferies, BofA Securities and Huatai Securities acting as joint sponsors. Founded in 2018, it is a biopharmaceutical company focusing on renal disease therapies. Its core product AP301, a phosphate binder for hyperphosphatemia, has completed China’s registrational Phase III trial, with an NDA submission expected in the near term.

Founded in 2018, Alebund Pharmaceuticals is a biopharmaceutical company dedicated to renal disease treatments. As of the latest practicable date, its clinical and preclinical pipeline comprises one core product AP301 and six other candidates. AP301 is a phosphate binder developed to treat hyperphosphatemia—one of the most common complications in dialysis patients with chronic kidney disease, representing a significant unmet medical need. It has completed China’s registrational Phase III trial, with a new drug application (NDA) expected soon, and is currently undergoing a global Phase III pivotal multi-regional clinical trial (MRCT) in the United States and China.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.

Tags：

Alebund IPO pass the listing hearing